Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft
Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft
复制标题
DOI：
10.1002/pros.21058
复制
发表时间：
2010-02
期刊：
影响因子：
--
通讯作者：
N. Terada;Y. Shimizu;T. Yoshida;Atsushi Maeno;T. Kamba;Takahiro Inoue;E. Nakamura;T. Kamoto;O. Ogawa
中科院分区：
文献类型：
--
作者：
N. Terada;Y. Shimizu;T. Yoshida;Atsushi Maeno;T. Kamba;Takahiro Inoue;E. Nakamura;T. Kamoto;O. Ogawa
抗雄激素戒断综合征（AWS）和替代抗雄激素治疗（AAT）有效性的潜在机制被认为是雄激素受体（AR）突变，导致对抗雄激素的反应改变。本研究的目的是使用携带W741 C突变体AR的新型前列腺癌异种移植物模型KUCaP-1（Yoshida等人，Cancer Res 2005; 65（21）：9611-9616）。
The mechanisms underlying antiandrogen withdrawal syndrome (AWS) and alternative antiandrogen therapy (AAT) effectiveness were assumed to be mutations in the androgen receptor (AR), which resulted in an altered response to antiandrogens. The aim of the present study was to test this assumption using the novel prostate cancer xenograft model KUCaP‐1 harboring the W741C mutant AR (Yoshida et al., Cancer Res 2005; 65(21): 9611–9616).